Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.

Pfizer will temporarily reduce deliveries to Europe of the company’s vaccine against Covid-19 while upgrading production capacity.

Billionaire entrepreneur Mark Cuban – best known as the owner of the Dallas Mavericks and an investor on the ABC business reality series “Shark Tank” – is diving into generic drugs with a new startup, dubbed Mark Cuban Cost Plus Drug Company.

Precision Medicine Group acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.

BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.

Johnson & Johnson is on track to roll out a single-shot coronavirus vaccine in March, and plans to have clear data on how effective it is by the end of January or early February, the U.S. healthcare company’s chief science officer said.

Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.

Amgen is partnering with Ann Arbor, Michigan-based EVOQ Therapeutics for a license and collaboration deal to discover and develop drugs for autoimmune disorders.

At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”

Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.